We're pleased to share that endogene.bio has been selected for the DayOne Healthtech Innovation 2026 Accelerator.
From nearly 240 applications across 47 countries, 15 HealthTech and TechBio companies were selected for this year’s cohort, focused on technologies shaping the future of Pharma R&D.
Over the next three months, we’ll work closely with pharma leaders, investors, and industry experts, strengthening our engagement with the industry as we advance our uterine health platform.
We look forward to working alongside the DayOne community as we continue building the future of uterine health.
About endogene.bio
endogene.bio generates high-resolution biological data from menstrual blood, unlocking a previously inaccessible layer of human uterine biology. Our platform enables disease understanding, patient stratification, and therapeutic discovery across uterine health.
